Publication Name	World Journal of Diabetes
Manuscript ID	13480
Country	Argentina

Received	2014-08-25 08:46
Peer-Review Started	2014-08-25 17:10
First Decision by Editorial Office Director
Return for Revision	2014-12-19 08:45
Revised	2015-01-29 23:54
Publication Fee Transferred
Second Decision by Editor	2015-08-27 11:31
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-08-31 15:23
Articles in Press	2015-08-31 15:23
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-09-06 12:28
Publish the Manuscript Online	2015-09-15 09:14

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Minireviews
Article Title	Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease
Manuscript Source	Invited Manuscript
All Author List	Ramiro A Sanchez, Hugo Sanabria, Cecilia de los Santos and Agustin J Ramirez
Funding Agency and Grant Number
Corresponding Author	Ramiro A Sanchez, MD, PhD, Professor, Head, Arterial Hypertension and Metabolic Unit, University Hospital, Fundación Favaloro, Av. Belgrano 1782, 4.º, Buenos Aires 1093, Argentina. rsanchez@ffavaloro.org
Key Words	Incretins; Hypertension; Cardiovascular effects; Dipeptidyl peptidase 4 inhibitors; Sodium-glucose co-transporter 2
Core Tip	The dipeptidyl peptidase IV inhibitors prevent the breakdown of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide, but also decrease the degradation of several vasoactive peptides. Dipeptidyl peptidase IV inhibitors have shown to have favorable effects in animal models of ischemia/reperfusion and in hypertension. Clinical studies are most under way and final results could give reliable information on cardiovascular protection. Selective inhibitors of renal sodium glucose transport 2 have been also evaluated in the prevention of cardiovascular outcomes in type 2 diabetes. However, data on car-diovascular outcomes and cardiovascular death are limited and long term studies are on-going, therefore it is premature to draw conclusions.
Publish Date	2015-09-15 09:14
Citation	Sanchez RA, Sanabria H, de los Santos C, Ramirez AJ. Incretins and selective renal sodium-glucose co-transporter 2 inhibitors in hypertension and coronary heart disease. World J Diabetes 2015; 6(11): 1186-1197
URL	http://www.wjgnet.com/1948-9358/full/v6/i11/1186.htm
DOI	http://dx.doi.org/10.4239/wjd.v6.i11.1186

Full Article (PDF)	WJD-6-1186.pdf
Full Article (Word)	WJD-6-1186.doc
Manuscript File	13480-Review.doc
Answering Reviewers	13480-Answering reviewers.pdf
Audio Core Tip	13480-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	13480-Conflict-of-interest statement.pdf
Copyright License Agreement	13480-Copyright assignment.pdf
Peer-review Report	13480-Peer-review(s).pdf
Scientific Misconduct Check	13480-Scientific misconduct check.pdf
Scientific Editor Work List	13480-Scientific editor work list.pdf